- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01251003
Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury
Safety of Autologous Human Umbilical Cord Blood Treatment for Traumatic Brain in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Traumatic brain injury is the primary cause of pediatric trauma related morbidity and mortality. Currently there is no reparative therapeutic option available, and all interventions are designed to prevent injury progression or secondary brain injury. Pre-clinical data suggest that progenitor cellular infusions may reduce the severity of injury by a number of proposed mechanisms. The current study proposes a Phase 1 Safety Trial using stored autologous UCB to treat patients that sustain a severe or moderate TBI, and have not fully recovered as measured by the Glasgow Outcome Score-Expanded/Child at 6 to 18 months post-injury. We have chosen to use one bank that uses standardized processing and storage protocol to reduce cell product variability.
Families who have banked hUCB at Cord Blood Registry, Inc. (CBR), will be prospectively notified of the possibility of using their child's stored UCB if they sustain a moderate or severe TBI and have a persistent deficit at 6-18 months. Prior to enrolling in the study, patients will have their medical records, imaging studies reviewed, and a telephone interview will determine potential eligibility and exclusion criteria. If eligible, the patients will travel to Houston to undergo a medical history and physical exam, neuropsychiatric evaluation, DT-MRI imaging of the brain, and baseline laboratory evaluation. The UCB will be shipped to the Center for Cell and Gene Therapy for reanimation and characterization/determination of release criteria of the cell product (contamination-free). The UCB will be infused intravenously and the patient will be monitored as an in-patient in the Pediatric Intensive Care Unit (PICU) located within Children's Memorial Hermann Hospital for 24 hours, after which the patient will be discharged but will return the next day for a final examination. Follow-up visits will occur back at UT-Houston at 180 days, 1 year and 2 years post-infusion - these visits will include medical history and physical exam, neurological and neuropsych evaluations, and DT-MRI imaging of the brain.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Medical School at Houston, Children's Memorial Hermann Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospital admission Glasgow Coma Score between 3 and 12 at the time of injury
- Injury occurring 6 to 18 months prior to study cord blood infusion (+/- 30 days)
- Ability of child and caregiver to travel to Houston, and stay for at least 4 days, and to return for all Follow-up visits
- Ability of child to understand (and speak) English
- Child's own cord blood banked at Cord Blood Registry
Exclusion Criteria:
- Inability to obtain all pertinent medical records, including pertinent physician notes, laboratory findings, and radiographic images, related to the original injury, hospitalization and rehabilitation
- Recent radiographic evidence of extensive stroke as evidenced by >100ml lesion
- Pre-injury history of seizure disorder and/or neurological impairment
- Obliteration of perimesencephalic cistern on initial head CT/MRI
- Initial hospital Intracranial Pressure (ICP) > 40
- Unhealed fractures or wounds including osteomyelitis
- Pneumonia, or chronic lung disease requiring oxygen
- Spinal cord injury as diagnosed by CT or MR imaging or by clinical findings
- Cord blood sample contamination
- Participation in a concurrent intervention study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine if autologous hUCB transplantation is safe and free of infusion related toxicity.
Time Frame: 0-21 days post cellular product infusion
|
0-21 days post cellular product infusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine if autologous hUCB transplantation improves post-TBI neuropsychological and imaging outcomes measures.
Time Frame: 6 months, 12 months, 24 months post cellular product infusion
|
6 months, 12 months, 24 months post cellular product infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles S Cox, Jr., MD, University of Texas Medical School at Houston
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-10-0061
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
-
Northeastern UniversityBrandeis UniversityRecruitingTraumatic Brain Injury | Mild Traumatic Brain Injury | TBI | Moderate Traumatic Brain InjuryUnited States
Clinical Trials on Autologous cord blood
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), SingaporeCompletedHypoxic Ischemic EncephalopathySingapore
-
Guangdong Women and Children HospitalRecruitingSafety Issues;Effect of DrugsChina
-
Guangdong Women and Children HospitalUnknownSafety Issues | Effect of DrugsChina
-
Children's Hospital of Fudan UniversityGuangzhou Women and Children's Medical Center; Maternal and Child Health Hospital...WithdrawnCerebral Infarction | Hypoxic Ischemic EncephalopathyChina
-
The University of Texas Health Science Center,...Texas Medical Center Regenerative Medicine ConsortiumRecruitingCongenital Diaphragmatic HerniaUnited States
-
MinYoung Kim, M.D.CHA UniversityCompletedGlobal Developmental DelayKorea, Republic of
-
James Baumgartner, MDCord Blood Registry, Inc.SuspendedPerinatal Arterial Ischemic StrokeUnited States
-
Michael CottenTerminatedHypoplastic Left Heart SyndromeUnited States
-
Duke UniversityThe Marcus Foundation; PerkinElmer, Inc.CompletedAutism Spectrum DisorderUnited States
-
Charles CoxNo longer available